Cargando…

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel

Detalles Bibliográficos
Autores principales:	Papp, Kim A., Melosky, Barbara, Sehdev, Sandeep, Hotte, Sebastien J., Beecker, Jennifer R., Kirchhof, Mark G., Turchin, Irina, Dutz, Jan P., Gooderham, Melinda J., Gniadecki, Robert, Hong, Chih-ho, Lambert, Jo, Lynde, Charles W., Prajapati, Vimal H., Vender, Ronald B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366052/ https://www.ncbi.nlm.nih.gov/pubmed/37410207 http://dx.doi.org/10.1007/s13555-023-00949-5

Ejemplares similares

Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2022)

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
por: Papp, Kim A., et al.
Publicado: (2021)

Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry
por: Gooderham, Melinda, et al.
Publicado: (2022)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

35158 Adaptations in the PURE registry in response to the COVID 19 pandemic: The impact of well-designed modifications in real-world data collection in a psoriasis registry
por: Lynde, Charles, et al.
Publicado: (2022)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
por: Vender, Ronald, et al.
Publicado: (2022)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America
por: Papp, Kim A., et al.
Publicado: (2019)

Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review
por: Papp, Kim A., et al.
Publicado: (2021)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers
por: Vender, Ronald B., et al.
Publicado: (2022)

Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome
por: Lima, Hermenio, et al.
Publicado: (2017)

The burden associated with generalized pustular psoriasis: A Canadian population-based study of inpatient care, emergency departments, and hospital- or community-based outpatient clinics
por: Tarride, Jean-Eric, et al.
Publicado: (2023)

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting
por: Papp, K.A., et al.
Publicado: (2022)

Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients
por: Levtchenko, Elena, et al.
Publicado: (2022)

35181 Baseline disease and population characteristics associated with a diagnosis of COVID 19: Data from the PURE registry
por: Albrecht, Lorne, et al.
Publicado: (2022)

Management of scalp psoriasis: current perspectives
por: Blakely, Kim, et al.
Publicado: (2016)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic, Milica, et al.
Publicado: (2021)

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody
por: Papp, K.A., et al.
Publicado: (2018)

Diagnosis of Generalized Pustular Psoriasis
por: Fujita, Hideki, et al.
Publicado: (2022)

Reverse koebnerization of primary cutaneous follicle center lymphoma following skin biopsy
por: Choi, Bohmyi, et al.
Publicado: (2021)

Return of Lymantria dispar dispar (gypsy moth): A case report
por: Haq, Mawiyah, et al.
Publicado: (2021)

Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
por: Campennì, Alfredo, et al.
Publicado: (2020)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)
por: Lynde, Charles W., et al.
Publicado: (2022)

The burden of palmoplantar pustulosis: A Canadian population-based study of inpatient care, emergency departments, and outpatient clinics
por: Tarride, Jean-Eric, et al.
Publicado: (2023)

Multidisciplinary expert panel report on fluid stewardship: perspectives and practice
por: Malbrain, Manu L. N. G., et al.
Publicado: (2023)

Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: A case report
por: Bose, Reetesh, et al.
Publicado: (2020)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Expert consensus guidance on respiratory physiotherapy and rehabilitation of patients with rib fractures: An international, multidisciplinary e-Delphi study
por: Battle, Ceri, et al.
Publicado: (2023)

Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis
por: Wu, J.J., et al.
Publicado: (2022)

Tapinarof for the treatment of psoriasis
por: Nogueira, Sofia, et al.
Publicado: (2022)

34304 Persistence and adherence to ixekizumab treatment in patients with moderate-to-severe psoriasis before and during COVID-19 pandemic: Results from the Canadian Patient Support Program
por: Gulliver, Wayne, et al.
Publicado: (2022)

Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel
por: Velloso, Elvira D. Rodrigues Pereira, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bblrlela3cpcqb8ipofj8s95se